

Global Acinetobacter Infections Treatment Market Analysis and Forecast 2024-2030

<https://marketpublishers.com/r/G752DDEA9FE4EN.html>

Date: April 2024

Pages: 197

Price: US\$ 4,950.00 (Single User License)

ID: G752DDEA9FE4EN

Abstracts

Summary

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

According to APO Research, The global Acinetobacter Infections Treatment market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Acinetobacter Infections Treatment include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics and Achaogen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Acinetobacter Infections Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Acinetobacter Infections Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Acinetobacter Infections Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acinetobacter Infections Treatment revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Acinetobacter Infections Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for

Acinetobacter Infections Treatment revenue, projected growth trends, production technology, application and end-user industry.

Acinetobacter Infections Treatment segment by Company

Entasis Therapeutics

Roche

Adenium Biotech

Vaxdyn

Hsiri Therapeutics

Aridis Pharmaceuticals

LegoChem Biosciences

Atterx Biotherapeutics

Achaogen

Peptilogics

Sealife PHARMA

Shionogi

Techulon

Tetraphase Pharmaceuticals

Acinetobacter Infections Treatment segment by Type

Sulbactam

Carbapenems

Aminoglycosides

Polymyxins

Tetracyclines

Others

Acinetobacter Infections Treatment segment by Pipeline

ETX2514

Nacubactam RG6080

Arenicin

VXD-001

Small Molecule Antibiotic

AR-401 mAB

LCB01-0371 (PO)

GN-4474

Antibacterial Antibody

Others

Acinetobacter Infections Treatment segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acinetobacter Infections Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acinetobacter Infections Treatment company

competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acinetobacter Infections Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

Contents

1 MARKET OVERVIEW

1.1 Product Definition

1.2 Acinetobacter Infections Treatment Market by Type

1.2.1 Global Acinetobacter Infections Treatment Market Size by Type, 2019 VS 2023 VS 2030

1.2.2 Sulbactam

1.2.3 Carbapenems

1.2.4 Aminoglycosides

1.2.5 Polymyxins

1.2.6 Tetracyclines

1.2.7 Others

1.3 Acinetobacter Infections Treatment Market by Pipeline

1.3.1 Global Acinetobacter Infections Treatment Market Size by Pipeline, 2019 VS 2023 VS 2030

1.3.2 ETX2514

1.3.3 Nacubactam RG6080

1.3.4 Arenicin

1.3.5 VXD-001

1.3.6 Small Molecule Antibiotic

1.3.7 AR-401 mAB

1.3.8 LCB01-0371 (PO)

1.3.9 GN-4474

1.3.10 Antibacterial Antibody

1.3.11 Others

1.4 Assumptions and Limitations

1.5 Study Goals and Objectives

2 ACINETOBACTER INFECTIONS TREATMENT MARKET DYNAMICS

2.1 Acinetobacter Infections Treatment Industry Trends

2.2 Acinetobacter Infections Treatment Industry Drivers

2.3 Acinetobacter Infections Treatment Industry Opportunities and Challenges

2.4 Acinetobacter Infections Treatment Industry Restraints

3 GLOBAL GROWTH PERSPECTIVE

- 3.1 Global Acinetobacter Infections Treatment Market Perspective (2019-2030)
- 3.2 Global Acinetobacter Infections Treatment Growth Trends by Region
 - 3.2.1 Global Acinetobacter Infections Treatment Market Size by Region: 2019 VS 2023 VS 2030
 - 3.2.2 Global Acinetobacter Infections Treatment Market Size by Region (2019-2024)
 - 3.2.3 Global Acinetobacter Infections Treatment Market Size by Region (2025-2030)

4 COMPETITIVE LANDSCAPE BY PLAYERS

- 4.1 Global Acinetobacter Infections Treatment Revenue by Players
 - 4.1.1 Global Acinetobacter Infections Treatment Revenue by Players (2019-2024)
 - 4.1.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players (2019-2024)
 - 4.1.3 Global Acinetobacter Infections Treatment Players Revenue Share Top 10 and Top 5 in 2023
- 4.2 Global Acinetobacter Infections Treatment Key Players Ranking, 2022 VS 2023 VS 2024
- 4.3 Global Acinetobacter Infections Treatment Key Players Headquarters & Area Served
- 4.4 Global Acinetobacter Infections Treatment Players, Product Type & Application
- 4.5 Global Acinetobacter Infections Treatment Players Commercialization Time
- 4.6 Market Competitive Analysis
 - 4.6.1 Global Acinetobacter Infections Treatment Market CR5 and HHI
 - 4.6.2 Global Top 5 and 10 Acinetobacter Infections Treatment Players Market Share by Revenue in 2023
 - 4.6.3 2023 Acinetobacter Infections Treatment Tier 1, Tier 2, and Tier

5 ACINETOBACTER INFECTIONS TREATMENT MARKET SIZE BY TYPE

- 5.1 Global Acinetobacter Infections Treatment Revenue by Type (2019 VS 2023 VS 2030)
- 5.2 Global Acinetobacter Infections Treatment Revenue by Type (2019-2030)
- 5.3 Global Acinetobacter Infections Treatment Revenue Market Share by Type (2019-2030)

6 ACINETOBACTER INFECTIONS TREATMENT MARKET SIZE BY APPLICATION

- 6.1 Global Acinetobacter Infections Treatment Revenue by Application (2019 VS 2023 VS 2030)

6.2 Global Acinetobacter Infections Treatment Revenue by Application (2019-2030)

6.3 Global Acinetobacter Infections Treatment Revenue Market Share by Application (2019-2030)

7 COMPANY PROFILES

7.1 Entasis Therapeutics

7.1.1 Entasis Therapeutics Company Information

7.1.2 Entasis Therapeutics Business Overview

7.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

7.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio

7.1.5 Entasis Therapeutics Recent Developments

7.2 Roche

7.2.1 Roche Company Information

7.2.2 Roche Business Overview

7.2.3 Roche Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

7.2.4 Roche Acinetobacter Infections Treatment Product Portfolio

7.2.5 Roche Recent Developments

7.3 Adenium Biotech

7.3.1 Adenium Biotech Company Information

7.3.2 Adenium Biotech Business Overview

7.3.3 Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

7.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio

7.3.5 Adenium Biotech Recent Developments

7.4 Vaxdyn

7.4.1 Vaxdyn Company Information

7.4.2 Vaxdyn Business Overview

7.4.3 Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

7.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio

7.4.5 Vaxdyn Recent Developments

7.5 Hsiri Therapeutics

7.5.1 Hsiri Therapeutics Company Information

7.5.2 Hsiri Therapeutics Business Overview

7.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

- 7.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio
- 7.5.5 Hsiri Therapeutics Recent Developments
- 7.6 Aridis Pharmaceuticals
 - 7.6.1 Aridis Pharmaceuticals Company Information
 - 7.6.2 Aridis Pharmaceuticals Business Overview
 - 7.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
 - 7.6.5 Aridis Pharmaceuticals Recent Developments
- 7.7 LegoChem Biosciences
 - 7.7.1 LegoChem Biosciences Company Information
 - 7.7.2 LegoChem Biosciences Business Overview
 - 7.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio
 - 7.7.5 LegoChem Biosciences Recent Developments
- 7.8 Atterx Biotherapeutics
 - 7.8.1 Atterx Biotherapeutics Company Information
 - 7.8.2 Atterx Biotherapeutics Business Overview
 - 7.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio
 - 7.8.5 Atterx Biotherapeutics Recent Developments
- 7.9 Achaogen
 - 7.9.1 Achaogen Company Information
 - 7.9.2 Achaogen Business Overview
 - 7.9.3 Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio
 - 7.9.5 Achaogen Recent Developments
- 7.10 Peptilogics
 - 7.10.1 Peptilogics Company Information
 - 7.10.2 Peptilogics Business Overview
 - 7.10.3 Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio
 - 7.10.5 Peptilogics Recent Developments
- 7.11 Sealife PHARMA
 - 7.11.1 Sealife PHARMA Company Information

- 7.11.2 Sealife PHARMA Business Overview
- 7.11.3 Sealife PHARMA Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
- 7.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio
- 7.11.5 Sealife PHARMA Recent Developments
- 7.12 Shionogi
 - 7.12.1 Shionogi Company Information
 - 7.12.2 Shionogi Business Overview
 - 7.12.3 Shionogi Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio
 - 7.12.5 Shionogi Recent Developments
- 7.13 Techulon
 - 7.13.1 Techulon Company Information
 - 7.13.2 Techulon Business Overview
 - 7.13.3 Techulon Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio
 - 7.13.5 Techulon Recent Developments
- 7.14 Tetrphase Pharmaceuticals
 - 7.14.1 Tetrphase Pharmaceuticals Company Information
 - 7.14.2 Tetrphase Pharmaceuticals Business Overview
 - 7.14.3 Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)
 - 7.14.4 Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
 - 7.14.5 Tetrphase Pharmaceuticals Recent Developments

8 NORTH AMERICA

- 8.1 North America Acinetobacter Infections Treatment Revenue (2019-2030)
- 8.2 North America Acinetobacter Infections Treatment Revenue by Type (2019-2030)
 - 8.2.1 North America Acinetobacter Infections Treatment Revenue by Type (2019-2024)
 - 8.2.2 North America Acinetobacter Infections Treatment Revenue by Type (2025-2030)
- 8.3 North America Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)
- 8.4 North America Acinetobacter Infections Treatment Revenue by Pipeline

(2019-2030)

8.4.1 North America Acinetobacter Infections Treatment Revenue by Pipeline

(2019-2024)

8.4.2 North America Acinetobacter Infections Treatment Revenue by Pipeline

(2025-2030)

8.5 North America Acinetobacter Infections Treatment Revenue Share by Pipeline

(2019-2030)

8.6 North America Acinetobacter Infections Treatment Revenue by Country

8.6.1 North America Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030)

8.6.2 North America Acinetobacter Infections Treatment Revenue by Country (2019-2024)

8.6.3 North America Acinetobacter Infections Treatment Revenue by Country (2025-2030)

8.6.4 U.S.

8.6.5 Canada

9 EUROPE

9.1 Europe Acinetobacter Infections Treatment Revenue (2019-2030)

9.2 Europe Acinetobacter Infections Treatment Revenue by Type (2019-2030)

9.2.1 Europe Acinetobacter Infections Treatment Revenue by Type (2019-2024)

9.2.2 Europe Acinetobacter Infections Treatment Revenue by Type (2025-2030)

9.3 Europe Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)

9.4 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2019-2030)

9.4.1 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024)

9.4.2 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2025-2030)

9.5 Europe Acinetobacter Infections Treatment Revenue Share by Pipeline (2019-2030)

9.6 Europe Acinetobacter Infections Treatment Revenue by Country

9.6.1 Europe Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030)

9.6.2 Europe Acinetobacter Infections Treatment Revenue by Country (2019-2024)

9.6.3 Europe Acinetobacter Infections Treatment Revenue by Country (2025-2030)

9.6.4 Germany

9.6.5 France

9.6.6 U.K.

9.6.7 Italy

9.6.8 Russia

10 CHINA

- 10.1 China Acinetobacter Infections Treatment Revenue (2019-2030)
- 10.2 China Acinetobacter Infections Treatment Revenue by Type (2019-2030)
 - 10.2.1 China Acinetobacter Infections Treatment Revenue by Type (2019-2024)
 - 10.2.2 China Acinetobacter Infections Treatment Revenue by Type (2025-2030)
- 10.3 China Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)
- 10.4 China Acinetobacter Infections Treatment Revenue by Pipeline (2019-2030)
 - 10.4.1 China Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024)
 - 10.4.2 China Acinetobacter Infections Treatment Revenue by Pipeline (2025-2030)
- 10.5 China Acinetobacter Infections Treatment Revenue Share by Pipeline (2019-2030)

11 ASIA (EXCLUDING CHINA)

- 11.1 Asia Acinetobacter Infections Treatment Revenue (2019-2030)
- 11.2 Asia Acinetobacter Infections Treatment Revenue by Type (2019-2030)
 - 11.2.1 Asia Acinetobacter Infections Treatment Revenue by Type (2019-2024)
 - 11.2.2 Asia Acinetobacter Infections Treatment Revenue by Type (2025-2030)
- 11.3 Asia Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)
- 11.4 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2019-2030)
 - 11.4.1 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024)
 - 11.4.2 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2025-2030)
- 11.5 Asia Acinetobacter Infections Treatment Revenue Share by Pipeline (2019-2030)
- 11.6 Asia Acinetobacter Infections Treatment Revenue by Country
 - 11.6.1 Asia Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030)
 - 11.6.2 Asia Acinetobacter Infections Treatment Revenue by Country (2019-2024)
 - 11.6.3 Asia Acinetobacter Infections Treatment Revenue by Country (2025-2030)
 - 11.6.4 Japan
 - 11.6.5 South Korea
 - 11.6.6 India
 - 11.6.7 Australia
 - 11.6.8 China Taiwan
 - 11.6.9 Southeast Asia

12 MIDDLE EAST, AFRICA, LATIN AMERICA

- 12.1 MEALA Acinetobacter Infections Treatment Revenue (2019-2030)
- 12.2 MEALA Acinetobacter Infections Treatment Revenue by Type (2019-2030)

- 12.2.1 MEALA Acinetobacter Infections Treatment Revenue by Type (2019-2024)
- 12.2.2 MEALA Acinetobacter Infections Treatment Revenue by Type (2025-2030)
- 12.3 MEALA Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)
- 12.4 MEALA Acinetobacter Infections Treatment Revenue by Pipeline (2019-2030)
 - 12.4.1 MEALA Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024)
 - 12.4.2 MEALA Acinetobacter Infections Treatment Revenue by Pipeline (2025-2030)
- 12.5 MEALA Acinetobacter Infections Treatment Revenue Share by Pipeline (2019-2030)
- 12.6 MEALA Acinetobacter Infections Treatment Revenue by Country
 - 12.6.1 MEALA Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030)
 - 12.6.2 MEALA Acinetobacter Infections Treatment Revenue by Country (2019-2024)
 - 12.6.3 MEALA Acinetobacter Infections Treatment Revenue by Country (2025-2030)
 - 12.6.4 Mexico
 - 12.6.5 Brazil
 - 12.6.6 Israel
 - 12.6.7 Argentina
 - 12.6.8 Colombia
 - 12.6.9 Turkey
 - 12.6.10 Saudi Arabia
 - 12.6.11 UAE

13 CONCLUDING INSIGHTS

14 APPENDIX

- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
 - 14.5.1 Secondary Sources
 - 14.5.2 Primary Sources
- 14.6 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Acinetobacter Infections Treatment Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030

Table 1. Sulbactam Major Manufacturers

Table 2. Carbapenems Major Manufacturers

Table 3. Aminoglycosides Major Manufacturers

Table 4. Polymyxins Major Manufacturers

Table 5. Tetracyclines Major Manufacturers

Table 6. Others Major Manufacturers

Table 7. Global Acinetobacter Infections Treatment Market Size Growth Rate by Pipeline (US\$ Million), 2019 VS 2023 VS 2030

Table 8. ETX2514 Major Manufacturers

Table 9. Nacubactam RG6080 Major Manufacturers

Table 10. Arenicin Major Manufacturers

Table 11. VXD-001 Major Manufacturers

Table 12. Small Molecule Antibiotic Major Manufacturers

Table 13. AR-401 mAB Major Manufacturers

Table 14. LCB01-0371 (PO) Major Manufacturers

Table 15. GN-4474 Major Manufacturers

Table 16. Antibacterial Antibody Major Manufacturers

Table 17. Others Major Manufacturers

Table 18. Acinetobacter Infections Treatment Industry Trends

Table 19. Acinetobacter Infections Treatment Industry Drivers

Table 20. Acinetobacter Infections Treatment Industry Opportunities and Challenges

Table 21. Acinetobacter Infections Treatment Industry Restraints

Table 22. Global Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Region (US\$ Million): 2019 VS 2023 VS 2030

Table 23. Global Acinetobacter Infections Treatment Market Size by Region (2019-2024) & (US\$ Million)

Table 24. Global Acinetobacter Infections Treatment Market Share by Region (2019-2024)

Table 25. Global Acinetobacter Infections Treatment Market Size by Region (2025-2030) & (US\$ Million)

Table 26. Global Acinetobacter Infections Treatment Market Share by Region (2025-2030)

Table 27. Global Acinetobacter Infections Treatment Revenue by Players (US\$ Million)

& (2019-2024)

Table 28. Global Acinetobacter Infections Treatment Revenue Market Share by Players (2019-2024)

Table 29. Global Acinetobacter Infections Treatment Key Players Ranking, 2022 VS 2023 VS 2024

Table 30. Global Acinetobacter Infections Treatment Key Players Headquarters & Area Served

Table 31. Global Acinetobacter Infections Treatment Players, Product Type & Application

Table 32. Global Acinetobacter Infections Treatment Players Commercialization Time

Table 33. Global Players Market Concentration Ratio (CR5 and HHI)

Table 34. Global Acinetobacter Infections Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)

Table 35. Global Acinetobacter Infections Treatment Revenue by Type 2019 VS 2023 VS 2030 (US\$ Million)

Table 36. Global Acinetobacter Infections Treatment Revenue by Type (2019-2024) & (US\$ Million)

Table 37. Global Acinetobacter Infections Treatment Revenue by Type (2025-2030) & (US\$ Million)

Table 38. Global Acinetobacter Infections Treatment Revenue Market Share by Type (2019-2024) & (US\$ Million)

Table 39. Global Acinetobacter Infections Treatment Revenue Market Share by Type (2025-2030) & (US\$ Million)

Table 40. Global Acinetobacter Infections Treatment Revenue by Pipeline 2019 VS 2023 VS 2030 (US\$ Million)

Table 41. Global Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 42. Global Acinetobacter Infections Treatment Revenue by Pipeline (2025-2030) & (US\$ Million)

Table 43. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2019-2024) & (US\$ Million)

Table 44. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2025-2030) & (US\$ Million)

Table 45. Entasis Therapeutics Company Information

Table 46. Entasis Therapeutics Business Overview

Table 47. Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 48. Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio

Table 49. Entasis Therapeutics Recent Development

Table 50. Roche Company Information

Table 51. Roche Business Overview

Table 52. Roche Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 53. Roche Acinetobacter Infections Treatment Product Portfolio

Table 54. Roche Recent Development

Table 55. Adenium Biotech Company Information

Table 56. Adenium Biotech Business Overview

Table 57. Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 58. Adenium Biotech Acinetobacter Infections Treatment Product Portfolio

Table 59. Adenium Biotech Recent Development

Table 60. Vaxdyn Company Information

Table 61. Vaxdyn Business Overview

Table 62. Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 63. Vaxdyn Acinetobacter Infections Treatment Product Portfolio

Table 64. Vaxdyn Recent Development

Table 65. Hsiri Therapeutics Company Information

Table 66. Hsiri Therapeutics Business Overview

Table 67. Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 68. Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio

Table 69. Hsiri Therapeutics Recent Development

Table 70. Aridis Pharmaceuticals Company Information

Table 71. Aridis Pharmaceuticals Business Overview

Table 72. Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 73. Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio

Table 74. Aridis Pharmaceuticals Recent Development

Table 75. LegoChem Biosciences Company Information

Table 76. LegoChem Biosciences Business Overview

Table 77. LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 78. LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio

Table 79. LegoChem Biosciences Recent Development

Table 80. Atterx Biotherapeutics Company Information

Table 81. Atterx Biotherapeutics Business Overview

Table 82. Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and

Gross Margin (US\$ Million) & (2019-2024)

Table 83. Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio

Table 84. Atterx Biotherapeutics Recent Development

Table 85. Achaogen Company Information

Table 86. Achaogen Business Overview

Table 87. Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 88. Achaogen Acinetobacter Infections Treatment Product Portfolio

Table 89. Achaogen Recent Development

Table 90. Peptilogics Company Information

Table 91. Peptilogics Business Overview

Table 92. Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (US\$ Million) & (2019-2024)

Table 93. Peptilogics Acinetobacter Infections Treatment Product Portfolio

Table 94. Peptilogics Recent Development

Table 95. Sealife PHARMA Company Information

Table 96. Sealife PHARMA Business Overview

Table 97. Sealife PHARMA Acinetobacter Infections Treatment Sales (Cases), Revenue (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 98. Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio

Table 99. Sealife PHARMA Recent Development

Table 100. Shionogi Company Information

Table 101. Shionogi Business Overview

Table 102. Shionogi Acinetobacter Infections Treatment Sales (Cases), Revenue (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 103. Shionogi Acinetobacter Infections Treatment Product Portfolio

Table 104. Shionogi Recent Development

Table 105. Techulon Company Information

Table 106. Techulon Business Overview

Table 107. Techulon Acinetobacter Infections Treatment Sales (Cases), Revenue (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 108. Techulon Acinetobacter Infections Treatment Product Portfolio

Table 109. Techulon Recent Development

Table 110. Tetrphase Pharmaceuticals Company Information

Table 111. Tetrphase Pharmaceuticals Business Overview

Table 112. Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Sales (Cases), Revenue (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 113. Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio

Table 114. Tetrphase Pharmaceuticals Recent Development

Table 115. North America Acinetobacter Infections Treatment Revenue by Type (2019-2024) & (US\$ Million)

Table 116. North America Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 117. North America Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 118. North America Acinetobacter Infections Treatment Revenue by Country (2019-2024) & (US\$ Million)

Table 119. North America Acinetobacter Infections Treatment Revenue by Country (2025-2030) & (US\$ Million)

Table 120. Europe Acinetobacter Infections Treatment Revenue by Type (2019-2024) & (US\$ Million)

Table 121. Europe Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 122. Europe Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 123. Europe Acinetobacter Infections Treatment Revenue by Country (2019-2024) & (US\$ Million)

Table 124. Europe Acinetobacter Infections Treatment Revenue by Country (2025-2030) & (US\$ Million)

Table 125. China Acinetobacter Infections Treatment Revenue by Type (2019-2024) & (US\$ Million)

Table 126. China Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 127. Asia Acinetobacter Infections Treatment Revenue by Type (2019-2024) & (US\$ Million)

Table 128. Asia Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 129. Asia Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 130. Asia Acinetobacter Infections Treatment Revenue by Country (2019-2024) & (US\$ Million)

Table 131. Asia Acinetobacter Infections Treatment Revenue by Country (2025-2030) & (US\$ Million)

Table 132. MEALA Acinetobacter Infections Treatment Revenue by Type (2019-2024) & (US\$ Million)

Table 133. MEALA Acinetobacter Infections Treatment Revenue by Pipeline (2019-2024) & (US\$ Million)

Table 134. MEALA Acinetobacter Infections Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US\$ Million)

Table 135. MEALA Acinetobacter Infections Treatment Revenue by Country (2019-2024) & (US\$ Million)

Table 136. MEALA Acinetobacter Infections Treatment Revenue by Country (2025-2030) & (US\$ Million)

Table 137. Research Programs/Design for This Report

Table 138. Authors List of This Report

Table 139. Secondary Sources

Table 140. Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Acinetobacter Infections Treatment Product Picture

Figure 2. Global Acinetobacter Infections Treatment Market Size Growth Rate by Type (US\$ Million), 2019 VS 2023 VS 2030

Figure 3. Global Acinetobacter Infections Treatment Market Size Share 2019 VS 2023 VS 2030

Figure 4. Sulbactam Picture

Figure 5. Carbapenems Picture

Figure 6. Aminoglycosides Picture

Figure 7. Polymyxins Picture

Figure 8. Tetracyclines Picture

Figure 9. Others Picture

Figure 10. Global Acinetobacter Infections Treatment Market Size Growth Rate by Pipeline (US\$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Acinetobacter Infections Treatment Market Size Share 2019 VS 2023 VS 2030

Figure 12. ETX2514 Picture

Figure 13. Nacubactam RG6080 Picture

Figure 14. Arenicin Picture

Figure 15. VXD-001 Picture

Figure 16. Small Molecule Antibiotic Picture

Figure 17. AR-401 mAB Picture

Figure 18. LCB01-0371 (PO) Picture

Figure 19. GN-4474 Picture

Figure 20. Antibacterial Antibody Picture

Figure 21. Others Picture

Figure 22. Global Acinetobacter Infections Treatment Market Size (US\$ Million) & (2019-2030)

Figure 23. Global Acinetobacter Infections Treatment Market Size, (US\$ Million), 2019 VS 2023 VS 2030

Figure 24. Global Acinetobacter Infections Treatment Market Share by Region: 2019 VS 2023 VS 2030

Figure 25. Global Acinetobacter Infections Treatment Players Revenue Share Top 10 and Top 5 in 2023

Figure 26. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 27. Global Acinetobacter Infections Treatment Revenue by Type (2019 VS 2023)

VS 2030) & (US\$ Million)

Figure 28. Global Acinetobacter Infections Treatment Revenue Market Share 2019 VS 2023 VS 2030

Figure 29. Global Acinetobacter Infections Treatment Revenue Market Share by Type (2019-2030)

Figure 30. Global Acinetobacter Infections Treatment Revenue by Pipeline (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 31. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2019 VS 2023 VS 2030)

Figure 32. Global Acinetobacter Infections Treatment Revenue Market Share by Pipeline (2019-2030)

Figure 33. North America Acinetobacter Infections Treatment Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 34. North America Acinetobacter Infections Treatment Revenue by Type (2025-2030) & (US\$ Million)

Figure 35. North America Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)

Figure 36. North America Acinetobacter Infections Treatment Revenue by Application (2025-2030) & (US\$ Million)

Figure 37. North America Acinetobacter Infections Treatment Revenue Share by Application (2019-2030)

Figure 38. North America Acinetobacter Infections Treatment Revenue Share by Country (2019-2030)

Figure 39. United States Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 40. Canada Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 41. Europe Acinetobacter Infections Treatment Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 42. Europe Acinetobacter Infections Treatment Revenue by Type (2025-2030) & (US\$ Million)

Figure 43. Europe Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)

Figure 44. Europe Acinetobacter Infections Treatment Revenue by Application (2025-2030) & (US\$ Million)

Figure 45. Europe Acinetobacter Infections Treatment Revenue Share by Application (2019-2030)

Figure 46. Europe Acinetobacter Infections Treatment Revenue Share by Country (2019-2030)

Figure 47. Germany Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 48. France Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 49. U.K. Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 50. Italy Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 51. Russia Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 52. Nordic Countries Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 53. China Acinetobacter Infections Treatment Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 54. China Acinetobacter Infections Treatment Revenue by Type (2025-2030) & (US\$ Million)

Figure 55. China Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)

Figure 56. China Acinetobacter Infections Treatment Revenue by Application (2025-2030) & (US\$ Million)

Figure 57. China Acinetobacter Infections Treatment Revenue Share by Application (2019-2030)

Figure 58. Asia Acinetobacter Infections Treatment Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 59. Asia Acinetobacter Infections Treatment Revenue by Type (2025-2030) & (US\$ Million)

Figure 60. Asia Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)

Figure 61. Asia Acinetobacter Infections Treatment Revenue by Application (2025-2030) & (US\$ Million)

Figure 62. Asia Acinetobacter Infections Treatment Revenue Share by Application (2019-2030)

Figure 63. Asia Acinetobacter Infections Treatment Revenue Share by Country (2019-2030)

Figure 64. Japan Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 65. South Korea Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 66. India Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million)

& (2019-2030)

Figure 67. Australia Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 68. China Taiwan Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 69. Southeast Asia Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 70. MEALA Acinetobacter Infections Treatment Revenue YoY Growth (2019-2030) & (US\$ Million)

Figure 71. MEALA Acinetobacter Infections Treatment Revenue by Type (2025-2030) & (US\$ Million)

Figure 72. MEALA Acinetobacter Infections Treatment Revenue Share by Type (2019-2030)

Figure 73. MEALA Acinetobacter Infections Treatment Revenue by Application (2025-2030) & (US\$ Million)

Figure 74. MEALA Acinetobacter Infections Treatment Revenue Share by Application (2019-2030)

Figure 75. MEALA Acinetobacter Infections Treatment Revenue Share by Country (2019-2030)

Figure 76. Mexico Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 77. South Korea Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

Figure 78. Brazil Acinetobacter Infections Treatment Revenue YoY Growth (US\$ Million) & (2019-2030)

I would like to order

Product name: Global Acinetobacter Infections Treatment Market Analysis and Forecast 2024-2030

Product link: <https://marketpublishers.com/r/G752DDEA9FE4EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G752DDEA9FE4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970